Division of Medical Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Clin Cancer Res. 2022 Jul 15;28(14):2977-2979. doi: 10.1158/1078-0432.CCR-22-1256.
In the search for targeting MAPK plus other pathways in NRAS-mutant melanoma, a phase Ib/II trial tested binimetinib plus ribociclib in metastatic melanoma. The response rate in the phase II trial was 19.5%, and the median progression-free survival was 3.7 months. See related article by Schuler et al., p. 3002.
在寻找针对 NRAS 突变黑色素瘤的 MAPK 加其他途径的方法时，一项 Ib/II 期试验测试了 binimetinib 加 ribociclib 在转移性黑色素瘤中的疗效。II 期试验的缓解率为 19.5%，中位无进展生存期为 3.7 个月。见 Schuler 等人的相关文章，第 3002 页。
